CME: Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)
ACCREDITATION EXPIRED: March 04, 2021
Activity Description / Statement of Need:
In this online, self-learning activity:
Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia A, a mutation in the gene for factor VIII (FVIII) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia A is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 5000 male births. The condition is diagnosed by measuring FVIII activity, and patients with severe hemophilia have FVIII activity of 1% or less.
Patients with severe hemophilia A are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.
This is a learning activity focused on Hemophilia A and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
Target Audience:
The following healthcare professionals: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with Hemophilia A.
This program is supported by an educational grant from Shire.
Release Date: March 04, 2019 -- Expiration Date: March 04, 2021
Faculty: Christopher Walsh, MD
Agenda
|
Faculty member introduction, disclosures, overview of Hemophilia A |
|
Major findings from ASH 2018, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) |
|
Applicability to clinical practice and patient cases, where relevant |
|
Concluding remarks |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the limitations of annual bleed rate as an epidemiological measure in Hemophilia A
- Define early prophylaxis in severe hemophilia A and describe its impact on osteochondral damage
- List evidence-supported benefits of extending clotting factor half lives
- Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia A, and apply them to patient cases
- Describe the emerging therapies in the treatment of hemophilia A
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Christopher Walsh, MD, PhD, Mount Sinai School of Medicine, New York, NY has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Shire.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies
Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies
Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)